Renalytix (RENX) Registration Filing summary

Company overview and business model

• Focuses on providing AI-enabled prognostic tests to identify patients at risk of progressive kidney function decline, addressing the global burden of chronic kidney disease affecting an estimated 850 million people.

• Developed kidneyintelX.dkd, the first FDA-authorized in vitro prognostic test for early risk assessment in kidney disease, leveraging technology licensed from leading medical institutions.

• Engaged in ongoing development of additional clinical tests from the KidneyIntelX platform through U.S. and international collaborations.

Financial performance and metrics

• Raised approximately $5 million in gross proceeds from the First Tranche and $7 million from the Second Tranche of a private placement in 2024, before fees and expenses.

• As of March 31, 2024, had 119,916,187 ordinary shares outstanding, increasing to 146,732,028 after the Second Closing.

• The company is classified as an emerging growth company and is subject to reduced public company reporting requirements until at least June 30, 2026.

Use of proceeds and capital allocation

• Will not receive any proceeds from the resale of shares by selling securityholders; all registration expenses are borne by the company, while selling expenses are borne by the securityholders.